Abstract:Carla Bolano-Diaz, 1 Jordi Diaz-Manera 1– 3 1 The John Walton Muscular Dystrophy Research Center, Newcastle University Translational and Clinical Research Institute, Newcastle Upon Tyne, UK; 2 Laboratori de Malalties Neuromusculars, Insitut de Recerca de l'Hospital de la Santa Creu i Sant Pau de Barcelona, Barcelona, Spain; 3 Centro de Investigación Biomédica en Red en Enfermedades Raras (CIBERER), Barcelona, Spain Correspondence: Jordi Diaz-Manera, The John Walton Muscular Dystrophy Research Center, Center for Life, Central Parkway, Newcastle Upon Tyne, NE13BZ, UK, Email Pompe disease is a genetic disorder produced by mutations in the GAA gene leading to absence or reduced expression of acid alpha-glucosidase, an enzyme that metabolizes the breakdown of glycogen into glucose. There are two main phenotypes, the infantile consisting of early onset severe weakness and cardiomyopathy, and the adult which is characterized by slowly progressive skeletal and respiratory muscle weakness. Enzymatic replacement therapy (ERT) has been available for Pompe disease for more than 15 years. Although the treatment has improved many aspects of the disease, such as prolonged survival through improved cardiomyopathy and acquisition of motor milestones in infants and slower progression rate in adults, ERT is far from being a cure as both infantile and adult patients continue to progress. This fact has prompted the development of improved or new enzymes and other treatments such as gene therapy or substrate reduction strategies. Here, we review the data obtained from randomized clinical trials but also from open-label studies published so far that have assessed the advantages and limitations of this therapy. Moreover, we also review the new therapeutic strategies that are under development and provide our opinion on which are the unmet needs for patients with this disease. Keywords: glycogen storage disease type II, Pompe disease, enzyme replacement therapy, recombinant human acid alpha-glucosidase, genetic therapy, clinical trials Pompe disease is a genetic glycogen storage disorder with an autosomal recessive pattern of inheritance. 1,2 The epidemiology of the disease is not clearly established although is suggested to be of almost 1:40,000 individuals. 3 There is however demographic variability, from countries with just a few cases described to others with a higher prevalence. 4–6 It is produced by mutations in the GAA gene localized to chromosome 17 which codifies for the enzyme acid alpha-glucosidase (AAG). 7 AAG is responsible for the breakdown of glycogen into glucose inside the lysosomes of the cells. A deficient enzyme activity leads to the accumulation of glycogen within cells of many tissues. However, patients' symptoms are mainly related to the dysfunction of skeletal, cardiac and smooth muscle and neurons, which are tissues with a high glucose demand. 2 Two main clinical disease phenotypes have traditionally been described: the infantile (classic and non-classic) and the late onset Pompe phenotypes. 2 Classic infantile onset Pompe disease (IOPD) typically presents early after birth with severe generalized muscle weakness, hypotonia, respiratory insufficiency and hypertrophic cardiomyopathy that, if left untreated, leads to death within the first year of life. IOPD patients can also show other associated symptoms such as hepatomegaly, feeding difficulties and macroglossia. 2,8 These patients have zero or very reduced AAG protein expression, which can be detected using Western blot (WB) analysis, a technique commonly described as cross-reactive immunologic material (CRIM) in the scientific papers. Those patients who have some residual enzyme activity are labeled as CRIM positive while those with no residual activity are labeled CRIM negative. 9 The term non-classic infantile onset Pompe disease is generally used to describe patients who have early onset of muscle weakness during the first two years of life with or without respiratory muscle dysfunction, but who do not develop cardiac involvement. 2 These patients can present very early in life with severe muscle weakness, or a bit later with a delay in the acquisition of motor milestones. As these patients grow, they develop other complications such as scoliosis, dysphagia, hepatomegaly, irritable bowel disease and joint contractures. 10 The term juvenile onset Pompe disease is used to describe patients who start presenting symptoms after 2 years of age, during childhood or adolescence. 10 Nowadays, this group of patients is usually included within the most severe end of patients with late onset Pompe disease (LOPD) and the term juvenile onset is being progressively abandoned. The cl -Abstract Truncated-

Molecular Approaches for the Treatment of Pompe Disease

Advances in Pompe Disease Treatment: From Enzyme Replacement to Gene Therapy

Pompe Disease: New Developments in an Old Lysosomal Storage Disorder

Glycogen storage disease types I and II: Treatment updates

Pompe disease: Unmet needs and emerging therapies

Therapeutic Options for the Management of Pompe Disease: Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management

Evaluating avalglucosidase alfa for the management of late-onset Pompe disease

Small-molecule inhibition of glycogen synthase 1 for the treatment of Pompe disease and other glycogen storage disorders

Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease

The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts

Combined proteomic and lipidomic studies in Pompe disease allow a better disease mechanism understanding

From Acid Alpha-Glucosidase Deficiency to Autophagy: Understanding the Bases of POMPE Disease

Interplay between mitochondrial dysfunction and lysosomal storage: challenges in genetic metabolic muscle diseases with a focus on infantile onset Pompe disease

Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase

Small molecule inhibition of glycogen synthase I reduces muscle glycogen content and improves biomarkers in a mouse model of Pompe disease

From Past to Present: Pompe Disease, Pseudodeficiency Alleles, and Diagnostic Challenges

First-in-Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe Disease

Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.

Correction of glycogenosis type 2 by muscle-specific lentiviral vector

Monitoring and Management of Respiratory Function in Pompe Disease: Current Perspectives

Preclinical lentiviral hematopoietic stem cell gene therapy corrects Pompe disease-related muscle and neurological manifestations